ArticleJCO oncology practice2026
Access Challenges in Allogeneic Hematopoietic Cell Transplant: Identifying At-Risk US States by Exploring Social Vulnerability, Physician Density, and Unmet Need.
Samantha E Watters, Christa L Meyer, Jaime M Preussler, Mary K S Senneka, Jeffery J Auletta, Dina L G Borzekowski
Abstract read
In one paragraphArticle in JCO oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors.
Christa L MeyerNMDP, Minneapolis, MN.
Mary K S SennekaNMDP, Minneapolis, MN.
Dina L G BorzekowskiUniversity of Maryland School of Public Health, College Park, MD.
Funding
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MBlood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4MTherapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2MCure Sickle CellOT3HL147741 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI MARY EAPEN, Mary Maresca Horowitz · 2018 to 2026
$37.7MHematopopietic Stem Cell TransplantationU01AI069197 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Effie W Petersdorf · 2005 to 2026
$18.9MClinical Significance of MHC Haplotypes in Hematopoietic Cell TransplantationR01CA100019 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETERSDORF, EFFIE W · 2003 to 2025
$9.1MImmuno and Epigenetics of Hematopoietic Cell TransplantationR01CA218285 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Effie W Petersdorf · 2017 to 2026
$5.6M1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic AnemiaU24HL157560 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI SHAW, BRONWEN · 2022 to 2025
$5.0MIntegrated Exchange and Storage of Current- and Future-Generation Immunogenomic DataR01AI128775 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JILL Allison HOLLENBACH, STEVEN JOHN MACK · 2017 to 2026
$4.5MNTP INFORMATION SYSTEMS SUPPORT27305C0011 · NIEHS · Z-TECH CORPORATION · 2007 to 2009
$4.3MImmunogenetics of Outcomes Disparities After Allogeneic HCTR01CA231838 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Effie W Petersdorf · 2018 to 2026
$3.7MHCMV-induced innate-like CD8 T cells and allogeneic HCT outcomeR01AI150999 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI HSU, KATHARINE C · 2021 to 2025
$3.6MCLC NIH HHS C0000008NCI NIH HHS P01 CA111412NCI NIH HHS R01 CA100019NCI NIH HHS R01 CA218285NCI NIH HHS R01 CA231838NCI NIH HHS R01 CA262899NCI NIH HHS U24 CA076518NHLBI NIH HHS OT3 HL147741NHLBI NIH HHS R01 HL155741NHLBI NIH HHS R01 HL171117NHLBI NIH HHS U24 HL138660NHLBI NIH HHS U24 HL157560NIAID NIH HHS R01 AI128775NIAID NIH HHS R01 AI150999NIAID NIH HHS R01 AI158861NIAID NIH HHS U01 AI069197NIAID NIH HHS U01 AI184132NIA NIH HHS R21 AG077024NIEHS NIH HHS 27305C0011NIEHS NIH HHS 27307C0009NIEHS NIH HHS 27307C0011NIEHS NIH HHS 27398C0011
6 · The paper itselfAbstract
purposeAccess to allogeneic hematopoietic cell transplantation (alloHCT) is limited by factors beyond physician control. A more complete picture of how barriers to alloHCT overlap is needed to target access-related initiatives. This study examined relationships between social vulnerability index (SVI), physician density (PD), and adult alloHCT unmet need to identify states at-risk of access challenges in the United States.
methodsFor this exploratory retrospective analysis, we aggregated SVI, Physician Compare, and 2018-2022 alloHCT unmet need data across all US counties. We defined PD as hematology-oncology/HCT providers per 10,000 population and dichotomized variables into low (≤50%) and high (>50%) percentiles. We identified counties with high SVI and unmet need and low PD as at-risk. Using multivariable linear regression, we assessed influences on unmet need.
resultsIn county-level models across all US counties, lower PD (b = -10.102,
conclusionWe found relationships among SVI, PD, and alloHCT unmet need to identify states at-risk for access impediments. Data can be examined to allocate resources to overcome barriers to alloHCT, with interventions targeting PD and SVI to improve access and equity in care.
Identifiers
PMID42372215
PMCPMC13531690
What OpenQuestion holds
Textmetadata
Read underepoch 390